PXS-5505
Based on 3 publication(s) in Google Scholar
PXS-5505 (LOX-IN-3 dihydrochloride monohydrate) (Compound 33) is an orally active lysyl oxidase (LOX) inhibitor. PXS-5505 can be used for fibrosis, cancer and angiogenesis research.
For research use only. We do not sell to patients.
- CAS No.: 2414974-55-1
- Formula: C13H17Cl2FN2O3S
- Molecular Weight:371.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PXS-5505
More
Biological Activity
Description
IC50 & Target
IC50: <1 μM (human LOXL2), <10 μM (bovine LOX)[1]
In Vitro
PXS-5505 (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of <10 μM and <1 μM, respectively[1].
PXS-5505 exhibits sustained inhibition of LOXL1 and LOXL2[1].
PXS-5505 is less active against SSAO/VAP-1 and MAO-B activities[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PXS-5505 (LOX-IN-3 dihydrochloride monohydrate) (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model[1].
PXS-5505 (LOX-IN-3 dihydrochloride monohydrate) (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats[1]
-
Dosage:30 mg/kg
-
Administration:Oral administration, single dose
-
Result:Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).
-
Animal Model:Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice[1]
-
Dosage:10 mg/kg
-
Administration:Oral gavage, daily for 14 days
-
Result:Increased kidney weight and thickness and reduced the area of fibrosis.
-
Animal Model:C57Bl/6 mice, Bleomycin-induced lung fibrosis model
-
Dosage:15 mg/kg
-
Administration:Oral gavage, daily for 21 days
-
Result:Significantly reduced the Ashcroft score and the lung weight.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2414974-55-1
-
Molecular Weight 371.26
-
Formula C13H17Cl2FN2O3S
-
SMILES
NC/C=C(F)/CS(=O)(C1=CC=CC2=C1N=CC=C2)=O.Cl.O.Cl
-
Synonyms
LOX-IN-3 dihydrochloride monohydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. [Abstract]2026 Feb 18. PMID: 41706704 -
iScience
MFAP5+ synovial fibroblasts drive LOX upregulation to promote osteoarthritis progression. [Abstract]2026 Jun 11;29(7):116286. PMID: 42325584 -
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PXS-5505 Related Classifications
HY-138625B Related Classifications
Powered by Bioz